Press Release: New Phase III data show Novartis -2-

References

1. Yoon H, Kato K, Raymond E et al. RATIONALE-306: Randomized, global,

placebo-controlled, double-blind Phase 3 study of tislelizumab plus

chemotherapy versus chemotherapy as first-line treatment for advanced

esophageal squamous cell carcinoma. Presented at ESMO-GI on 30 June 2022

(#LBA1).

2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:

GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in

185 countries. CA: a cancer journal for clinicians. 2021;71(3):209-249.

3. American Cancer Society. Key statistics for esophageal cancer. Accessed

March 1,

2022. https://www.cancer.org/cancer/esophagus-cancer/about/key-statistics

.html

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Anja von Treskow Michael Billings

Novartis External Communications Novartis Oncology

+41 79 392 8697 (mobile) +1 201 400 1854 (mobile)

anja.von_treskow@novartis.com michael.billings@novartis.com

Julie Masow

Novartis US External Communications

+1 862 579 8456

Julie.masow@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Alina Levchuk +1 862 778 3372

Isabella Zinck +41 61 324 7188 Parag Mahanti +1 973 876 4912

(END) Dow Jones Newswires

June 30, 2022 04:00 ET (08:00 GMT)